Vitamin B1

CCP: Treatment of thiamine deficiency (including thiamine deficiency in pregnancy associated with neuropathy)

CCP: Beriberi (dry or wet variety)

CCP: Wernicke encephalopathy

CCP: Cardiovascular disease due to thiamine deficiency

CCP: IV dextrose to individuals with marginal thiamine status to avoid precipitation of heart failure

• Hypersensitivity

Absorption: Rapid

Half-life: Unknown

Central nervous system:

• Flushing sensation, restlessness

Dermatologic:

• Diaphoresis, pruritus, skin sclerosis (at the injection site following IM administration), urticaria

Gastrointestinal:

• Nausea

Hematologic & oncologic:

• Hemorrhage (into the gastrointestinal tract)

Hypersensitivity:

• Anaphylaxis (following IV administration), angioedema, hypersensitivity reaction (following IV administration)

Local:

• Tenderness at injection site (following IM administration)

Neuromuscular & skeletal:

• Weakness

Respiratory:

• Cyanosis, pharyngeal edema, pulmonary edema

• Hypersensitivity reactions: Have been reported following repeated parenteral doses; consider skin test in individuals with history of allergic reactions.
• Dextrose: Administration of dextrose may precipitate acute symptoms of thiamine deficiency; use caution when thiamine status is marginal or suspect.
• Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of > 4 to 5 mcg/kg/day is associated with CNS and bone toxicity.

• Etamsylate
• Dextrose